摘要
来那度胺作为一种免疫调节性药物,在惰性B细胞淋巴瘤治疗中具有显著活性.基于淋巴瘤病理类型复杂、疾病分子遗传学异常和临床表现异质性强的特点,来那度胺在其他类型尤其是侵袭性淋巴瘤中的应用尚存争议.中国抗癌协会淋巴瘤专业委员会结合多项前瞻性临床研究及真实世界的数据制订了本共识,详细介绍了来那度胺在常见惰性和侵袭性淋巴瘤治疗中的疗效、用药方法、不良反应和特殊人群的剂量调整以及注意事项等,旨在为临床医生规范合理使用来那度胺治疗淋巴瘤患者提供指导和帮助.
Abstract
Lenalidomide,a potent immunomodulatory agent,has been demonstrated to have significant efficacy in indolent B-cell lymph-oma treatment.However,its adoption into clinical practice remains a subject of debate for other subtypes of lymphoma,particularly ag-gressive B-cell lymphoma.This controversy stems from the intricate classification of lymphoma subtypes,coupled with disease heterogen-eity from genetic abnormalities and clinical manifestations.To address these challenges,the Lymphoma Committee of China Anti-Cancer As-sociation has developed a comprehensive expert consensus on the clinical utilization of lenalidomide for lymphoma,based on pivotal pro-spective clinical trials and real-world evidences.The consensus comprehensively introduces lenalidomide monotherapy and combination re-gimens,delineating their efficacy across common lymphoma subtypes.Furthermore,it outlines recommendations for administration,dose adjustment in response to adverse effects and special populations,as well as precautions.This expert consensus provides physicians with a robust framework for personalized clinical applications of lenalidomide in the management of lymphoma with safety and effectiveness.
NETL
NSTL
万方数据